Revolution Medicines plans European rollout of pancreatic cancer drug

Revolution Medicines is laying the groundwork for a broad European commercial rollout of its pancreatic cancer drug, signaling confidence in its ability to bring the therapy to market without relying on a local partner to help sell it.

Following impressive clinical data against the notoriously difficult-to-treat cancer, analysts forecast peak annual global sales of $11.5 billion for Revolution’s Rasonque, which won speedy US approval in August after an FDA expedited review....